KRAS and neoplasm: As proven in the present study, the list of genes from the 44-gene panel more frequently mutated in BOT compared to the other tumor groups (FANCB, SEM1, FANCA, BRCA2, CHEK2, MUTYH, RAD50) was much longer than analogically altered genes in the hot-spot panel (KRAS only).